<DOC>
	<DOC>NCT00079911</DOC>
	<brief_summary>This clinical research study will be an international trial evaluating the safety and effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression of repeated genital herpes infections in HIV-infected subjects with CD4+ count &lt;100 cells/mm3.</brief_summary>
	<brief_title>A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>CD4+ lymphocyte count &lt;100cells/mm3 at the screening visit. Documented history of HIV infections Must have received stable, combination anti HIV drugs for at least 4 months immediately prior to participation, and per the investigator, are unlikely to require change in antiHIV drugs during the sixmonth study. Laboratory confirmation of genital herpes (a positive Herpes Simplex Virus2 antibody test). 3 or more outbreaks of genital herpes in the previous 12 months if not on genital herpes medicines currently. 3 or more outbreaks of genital herpes per year in the period prior to beginning of treatment for chronic genital herpes. Kidney diseases. Liver diseases. Known allergic reactions to VALTREX (valaciclovir), ZOVIRAX (acyclovir), FAMVIR (famciclovir), or CYTOVENE (ganciclovir). Vomiting syndrome. Must be willing to discontinue taking current genital herpes medicines 1 week prior to participation. Active AIDSindicator conditions, as defined by CDC Category C. Other protocol inclusion and exclusion criteria to be evaluated by the research physician.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Herpes</keyword>
	<keyword>Genital Herpes</keyword>
	<keyword>HIV</keyword>
	<keyword>HSV</keyword>
</DOC>